Evaluating the ability of visual images to inform college women about the link between smoking and cervical intraepithelial neoplasia (CIN) and to motivate quitting: Critical dimensions

Background. Because cervical intraepithelial neoplasia (CIN, or dysplasia) is associated with behavioral factors, health education is an important part of the care of patients at risk for this disease. Smoking, which is strongly associated with CIN and cancers, is particularly important because smoking cessation, even after the onset of CIN, improves outcomes. This study is part of an effort to identify effective ways to convey information about the association between smoking and CIN to at-risk women.Methods. We created 8 images to systematically incorporate a range of artistic approaches to inform viewers about the relationship between smoking and CIN. College women smokers were recruited to participate. Participants rated the images on the extent to which they attracted attention and motivated smoking cessation.Results. Significant differences were identified in the response of this population to visual images differing in content and style. Informative images were more compelling than those that were emotive.conclusions. Further exploration is warranted to improve our understanding of how visual forms of health education can impact smoking cessation by those at risk for cervical cancer.     

The effect of improved readability scores on consumers’ perceptions of the quality of health information on the internet

Background. Recent growth and use of the internet as a source of health information has raised concerns about consumers’ ability to comprehend this information. Although health scholars argue that writing web pages at an eighth-grade level or lower will help patients, few studies involve actual readers to investigate the effects of improved readability scores on partient’s perceptions of this information.Methods. This study examines American consumer evaluations of web pages written at different grade reading levels. In spring of 2005, a community-wide intercept survey was performed in a regional hub city in southeastern Ohio. Five hundred nineteen participants were randomly assigned to receive one of three messages discussing lung cancer prevention: one written at the eighth grade level, one at the ninth grade level, and one at the fist year college level. Independentt-tests were conducted to compare the messages on measures of perceived trustworthiness, truthfulness, readability, and completeness.Results. Improving the reading level of online information had no significant effect on consumers’ evaluations of the messages’ readability or completeness, nor a consistent effect on the perceived truthfulness or trustworthiness of the message.Conclusions. The results suggest that by simply changing the readability level of online information may not improve consumers; evaluation of the quality of health information on the internet. The authors offer alternative possibilities for why some sources of online health information may be seen as more valuable than others.     

Family history of colorectal cancer: A determinant of advanced adenoma stage or adenoma multiplicity?

A family history of colorectal cancer may increase colorectal cancer risk by influencing adenoma growth or enhancing the formation of new lesions. Data of men from the prospective Health Professionals Follow‐Up Study who underwent an endoscopy between 1986 and 2004 were used to evaluate whether a family history of colorectal cancer is associated with adenoma multiplicity or advanced adenoma stage (≥1 cm, histology with villous component or carcinoma in situ). 21.4% of the 3,881 adenoma patients and 13.9% of the 24,959 adenoma‐free men had a first‐degree relative with colorectal cancer. Thousand four hundred and ninety‐six men were classified as having advanced and 1,507 as having nonadvanced adenomas. Six hundred and twenty‐two men had multiple and 1,985 had single adenomas in the distal colon and rectum. A family history of colorectal cancer was similarly associated with advanced and nonadvanced adenomas [multivariable odds ratio (OR) (95% confidence interval): advanced vs. nonadvanced, 0.98 (0.82–1.17), advanced vs. adenoma‐free: 1.67 (1.47–1.91), nonadvanced vs. adenoma‐free: 1.70 (1.49–1.94)], although potential differences according to adenoma location were seen. A family history of colorectal cancer was more strongly associated with multiple distally located adenomas [odds ratio (95% confidence interval): multiple vs. single, 1.35 (1.09–1.68), multiple vs. no distally located adenomas: 2.02 (1.67–2.44), single vs. no distally located adenomas: 1.49 (1.32–1.68)]. The number of adenomas was also positively associated with a family history of colorectal cancer. Our findings suggest that at the population level, heritable factors may be more important in earlier stages of adenoma formation than at stages of adenoma advancement for at least distally located adenomas. © 2009 UICC     

Medical oncology patients’ preferences with regard to health care: development of a patient-driven questionnaire

BackgroundTo improve quality of care for cancer patients, it is important to have an insight on the patient's view on health care and on their specific wishes, needs and preferences, without restriction and without influence of researchers and health care providers. The aim of this study was to develop a questionnaire assessing medical oncology patients’ preferences for health care based on their own input.Patients and methodsItems were generated using 10 focus group interviews with 51 cancer patients. A preliminary questionnaire was handed out to 681 patients of seven Dutch departments of medical oncology. Explorative factor analysis was carried out on the 386 returned questionnaires (response 57%).ResultsFocus group interviews resulted in a preliminary questionnaire containing 136 items. Explorative factor analysis resulted in a definitive questionnaire containing 123 items (21 scales and eight single items). Patients rated expertise, safety, performance and attitude of physicians and nurses as the most important issues in cancer care.ConclusionThis questionnaire may be used to assess preferences of cancer patients and to come to a tailored approach of health care that meets patients’ wishes and needs.     

What did you think of the hematology/oncology rotation? A survey of internal medicine residents

Background. To evaluate responses of residents to a hematology/oncology rotation.Methods. A self-administered mail survey among internal medicine residents in a university-based training program who were required to complete a hematology/oncology rotation at a comprehensive cancer center.Results. The majority of the residents rated the duration of the rotation as adequate and quality as excellent or good. It had a positive impact on certain knowledge areas, general opinion about hematology/oncology, preparation for board examination, and motivation to pursue this subspecialty, especially among residents who had performed additional electives.Conclusion. A hematology/oncology rotation received a generally positive evaluation from internal medicine residents.     

Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations

Background. Accepted practices of informed consent often result in suboptimal patient understanding of research studies.Methods. This pilot study aimed to assess trial-specific tailored materials, compared to a widely used generic booklet about clinical trials, randomly assigned to 118 candidates for cancer clinical trials. Study outcomes were: satisfaction with decision-making; satisfaction with materials; and subjective understanding of the clinical trial.Results. There were no major differences between groups. Participants rated tailored materials higher as a useful reference.Conclusions. Trial-specific materials hold utility for reference during clinical trials. Studies of informed consent are feasible, although important factors limit research.     

Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study

Purpose: This phase I study was designed to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the paclitaxel–gemcitabine combination in a biweekly schedule in chemotherapy-naive patients with advanced non small-cell lung cancer (NSCLC). Patients and methods: Treatment was administered on an outpatient basis every 2 weeks: paclitaxel over a 1-h IV infusion and gemcitabine as a 30-min IV infusion immediately following paclitaxel. Results: Twenty-nine patients were treated at six different dose levels, ranging from paclitaxel 135–175 mg/m² and gemcitabine 1,500–3,000 mg/m². A total of 198 cycles were administered (median 7, range 1–13). DLTs in the first two cycles were grade 4 neutropenia and myocardial ischemia at the dose level paclitaxel/gemcitabine 150/2,000 mg/m², febrile neutropenia and grade 4 neutropenia at the dose level paclitaxel/gemcitabine 175/2,500 mg/m², fatal pneumonitis, sudden death and grade 3 neutropenia at the dose level paclitaxel/gemcitabine 175/3,000 mg/m². The MTD was paclitaxel 175 mg/m² and gemcitabine 2,500 mg/m². The average dose intensity at this dose level was 98%. The overall intent-to-treat response rate was 35.7% (95% confidence interval [CI] 17.97% - 53.47%). Overall median survival was 36 weeks (95% CI, 24-48). Conclusion: Paclitaxel and gemcitabine can be safely administered at a high dose intensity on an every-other-week schedule. The recommended phase II dose is paclitaxel 175 mg/m² and gemcitabine 2,500 mg/m².     

Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin

Purpose: Prospective assessment of quality of life (QoL) in patients with refractory, residual or recurrent ovarian cancer receiving whole abdomen hyperthermia and intravenous liposomal doxorubicin chemotherapy.

Methods: Treatment consisted of six cycles of intravenous liposomal doxorubicin at 40?mg?m² followed by whole abdomen hyperthermia with each cycle delivered every 4 weeks. QoL assessment was performed at baseline, prior to each cycle of chemotherapy and every 3 months during follow-up using self-administered questionnaires. Global QoL was rated on a seven-point scale and specific domains of QoL, disease related symptoms and treatment related toxicity were rated on a four-point scale.

Results: Thirty-two patients were enrolled on the study and 129?QoL questionnaires were completed. Average age was 57.9 (range 45–76); nine patients had persistent and 23 recurrent disease. Ten patients completed six cycles of therapy. Three patients returned follow-up surveys. Subjects rated their overall QoL and health at baseline as above average with mean scores 5.10 (95% CI?=?4.62?5.58) and 4.66 (95% CI?=?4.23?5.08), respectively. No significant change in overall QoL was found between baseline and cycles 4–6 of therapy. Mean ratings of overall health and subject reported differences in QoL between cycles were not significantly changed during therapy. Limited follow-up data were available, but scores suggest possible improvement in QoL for patients completing all therapy. Subjects rated the greatest negative impact on QoL in areas of role functioning and social functioning, where the mean (SD) over all cycles was 2.00 (0.67) and 1.98 (0.70), respectively. For physical symptoms, fatigue and sleep disturbance had the most negative impact on QoL with means (SD) of 2.26 (0.62) and 1.91 (0.70). The moderate treatment related toxicity seen in this study did not significantly impact patients reported QoL.

Conclusions: Patients with unfavourable ovarian cancer responding to intravenous liposomal doxorubicin and whole abdomen hyperthermia maintained above average QoL during therapy. Limited data on patients completing protocol therapy demonstrated possible improvement in QoL.     

Associations between unprocessed red and processed meat,poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies

Reports relating meat intake to prostate cancer risk are inconsistent. Associations between these dietary factors and prostate cancer were examined in a consortium of 15 cohort studies. During follow‐up, 52,683 incident prostate cancer cases, including 4,924 advanced cases, were identified among 842,149 men. Cox proportional hazard models were used to calculate study‐specific relative risks (RR) and then pooled using random effects models. Results do not support a substantial effect of total red, unprocessed red and processed meat for all prostate cancer outcomes, except for a modest positive association for tumors identified as advanced stage at diagnosis (advanced(r)). For seafood, no substantial effect was observed for prostate cancer regardless of stage or grade. Poultry intake was inversely associated with risk of advanced and fatal cancers (pooled multivariable RR [MVRR], 95% confidence interval, comparing ≥45 vs. <5 g/day: advanced 0.83, 0.70–0.99; trend test p value 0.29), fatal, 0.69, 0.59–0.82, trend test p value 0.16). Participants who ate ≥25 versus <5 g/day of eggs (1 egg ～ 50 g) had a significant 14% increased risk of advanced and fatal cancers (advanced 1.14, 1.01–1.28, trend test p value 0.01; fatal 1.14, 1.00–1.30, trend test p value 0.01). When associations were analyzed separately by geographical region (North America vs. other continents), positive associations between unprocessed red meat and egg intake, and inverse associations between poultry intake and advanced, advanced(r) and fatal cancers were limited to North American studies. However, differences were only statistically significant for eggs. Observed differences in associations by geographical region warrant further investigation.     

Predictors of new screening for African American men participating in a prostate cancer educational program

Background. African American (AA) men continue to have a greater than twofold risk of dying from prostate cancer compared to Whites. Methods. This community-based intervention study employed a quasi-experimental, delayed-control (cross-over) design with randomization at the church-level (N=345 AA men). Results. Logistic regression analyses revealed that the level of knowledge (b=.61, P<.05, Exp (B)=1.84), the perception of risk (b=2.99, P<.01, Exp (B)=19.95), and having insurance (b=3.20, P<.01, Exp (B)=24.65) significantly increased the odds of participants who needed screening getting screened during study. Discussion. This study demonstrated the need for education, community involvement, and increased access to encourage minority men to obtain needed health screenings.     

290. Phase I Study of Pemetrexed (ALIMTA) and Epirubicin in Patients with Locally Advanced or Metastatic Breast Cancer

Background. Pemetrexed is a novel antifolate that inhibits TS, DHFR, and GARFT. Both pemetrexed and epirubicin have documented efficacy in breast cancer. Objectives. To determine the maximum tolerated dose (MTD) of pemetrexed and epirubicin in combination in patients with advanced breast cancer. Methods. Pemetrexed and epirubicin were sequentially administered as 10 min infusions, on day 1 of a 21-day cycle. Folic acid and vitamin B12 were given to reduce incidence and severity of toxicities reported in earlier pemetrexed studies. Preliminary results. Twenty-two female patients ages 35–74 years (median 54 years) with PS 0-2 were enrolled. Five patients had received prior neoadjuvant (1) or adjuvant (4) chemotherapy. Patients received 1–8 cycles (median 6) of study drugs. Of 116 cycles administered, there were 12 dose reductions (G4 neutropenia) and 10 dose delays (transaminitis [5], neutropenic fever [1], and scheduling conflicts [4]). G3/4 neutropenia (15/22) was the most common hematologic toxicity. Neutropenic fever was the only G3/4 non-hematologic toxicity [1]. One patient discontinued due to recurrence of G4 neutropenia after 2 dose reductions. MTD was reached at dose level 3 with dose-limiting toxicities (DLTs) in 3/12 pts (neutropenic fever [1] and G4 neutropenia 5 days [2]). To date, 8 PRs and 5 stable disease (SD) have been reported among 14 patients with mature follow up. Conclusion. This combination is well tolerated. Although MTD was reached at dose level 3, enrollment at pemetrexed 600 mg/m² and epirubicin 75 mg/m² is ongoing to establish the best recommended phase II regimen.     

Sources of health information among Chinese immigrants to the Pacific Northwest

Background. Chinese immigrants to North America experience cancer-related health disparities and underutilize preventive care. Little is known about Chinese immigrants' sources of health information. Methods. A population-based survey of Chinese immigrants was conducted in Vancouver, British Columbia, Canada and Seattle, Washington. Results. The study group included 899 individuals. Less than three fourths of the respondents reported receiving health information from health care providers, and only a minority used the Internet as a source of health information. We found significant differences between the sources of health information in Seattle and Vancouver. Conclusions. Health educators should consider available media outlets as well as the characteristics of a target community when planning intervention programs for Chinese immigrants.     

How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide

Summary Background. Tamoxifen has been shown to reduce the incidence of invasive breast cancer in women at higher risk. Translating these research results to clinical practice is challenging. Our objective was to develop and evaluate a decision-making guide and process that can be used in clinical practice to inform eligible women of chemoprevention with tamoxifen. Methods. A decision guide explaining the benefits and risks of tamoxifen was developed with input from health care professionals and two focus groups of women both with and without cancer. Following consent, 51 eligible women presenting to a multi-disciplinary diagnostic facility for breast problems were given the decision guide/questionnaire to read, fill out and return by mail. Women with further questions or wanting to take tamoxifen were encouraged to re-contact their physicians. Results. Atypia was seen in 60% of subjects. Median 5-year Gail risk was 3.7 (range 1.7–9.4). Only 6 (11.8% 95% CI = 2.9, 20.6%) women reported they would like to take tamoxifen while 6 (11.8% 95% CI = 2.9, 20.6%) remained uncertain. Conclusion. We have developed a decision-making guide and process that is acceptable to providers and women to identify and inform women at higher risk of breast cancer with regard to chemoprevention with tamoxifen. Few women in this select group, when provided with a balanced decision guide, wished to pursue chemoprevention with tamoxifesn     

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Purpose: To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of MTA, a novel antifolate compound which inhibits the enzymes thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT), and dihydrofolate reductase (DHFR). Methods: Patients with advanced solid tumors were given MTA intravenously over 10 min every 21 days. Dose escalation was based on the modified continual reassessment method (MCRM), with one patient treated at each minimally toxic dose level. Pharmacokinetic studies were performed in all patients. Results: A total of 37 patients (27 males, 10 females, median age 59 years, median performance status 90%) were treated with 132 courses at nine dose levels, ranging from 50 to 700 mg/m². The MTD of MTA was 600 mg/m², with neutropenia and thrombocytopenia, and cumulative fatigue as the dose-limiting toxicities. Hematologic toxicity correlated with renal function and mild reversible renal dysfunction was observed in multiple patients. Other nonhematologic toxicities observed included mild to moderate fatigue, anorexia, nausea, diarrhea, mucositis, rash, and reversible hepatic transaminase elevations. Three patients expired due to drug-related complications. Pharmacokinetic analysis during the first course of treatment at the 600 mg/m² dose level demonstrated a mean harmonic half-life, maximum plasma concentration (Cpmax), clearance (CL), area under the curve (AUC), and apparent volume of distribution at steady state (Vdss) of 3.08 h, 137 μg/ml, 40.0 ml/min per m², 266 μg · h/ml, and 7.0 l/m², respectively. An average of 78% of the compound was excreted unchanged in the urine. Partial responses were achieved in two patients with advanced pancreatic cancer and in two patients with advanced colorectal cancer. Minor responses were obtained in six patients with advanced colorectal cancer. Conclusions: The MTD and dose for phase II clinical trials of MTA when administered intravenously over 10 min every 21 days was 600 mg/m². MTA is a promising new anticancer agent. Received: 20 October 1998 / Accepted: 30 March 1999     

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

Advanced breast cancer (BC) is associated with heavier treatments and poorer prognosis than early BC. Despite mammographic screening, advanced BC incidence remains stable. Little is known about risk factors differentially associated with advanced BC. We analyzed factors predicting for postmenopausal advanced vs. early BC in the E3N cohort. E3N has been prospectively following 98,995 French women aged 50–65 years at baseline since 1990. Hazard ratios (HRs) and 95% confidence intervals (CIs) for advanced and early invasive BC were estimated with multivariate Cox competing risk hazard models. With a median follow-up of 15.7 years, 4,941 postmenopausal BC were diagnosed, including 1,878 (38%) advanced BC. Compared to early BC, advanced BC was differentially associated with excess weight (HR 1.39 [95% CI = 1.26–1.53] vs. 1.08 [95% CI = 1.00–1.17], p_homogeneity < 0.0001) and living in a rural area (HR 1.14 [95% CI = 1.00–1.31] vs. 0.93 [95% CI = 0.82–1.04], p_homogeneity 0.02). Excess weight was the only differential risk factor for advanced BC for hormone-dependent BC and for women compliant with screening recommendations. Previous mammography was associated with reduced advanced BC risk (HR 0.86 [95% CI = 0.73–1.00]) and increased early BC risk (HR 1.36 [95% CI = 1.18–1.56], p_homogeneity < 0.0001), but only for hormone-dependent BC. Excess weight appears to be mostly associated with advanced BC, especially hormone-dependent BC. These results add to the evidence for maintaining weight within the recommended limits.     

Disseminating end-of-life Education to Cancer Centers: Overview of program and of evaluation

Background. Systematic provision of compassionate end-of-life (EOL) care requires strategic training of health professionals. Disseminating EOL Education to Cancer Centers (DELEtCC) targeted education of interdisciplinary institutional teams.Methods. Competitively-selected two-person teams participated in a national three-day EOL conference. Nationally recognized faculty created and presented the curriculum. Project faculty supported teams over 18 months as they implemented EOL goals. Conference evaluations were very positive.Results. Independent participant and administrative evaluations reported successful implementation of goals aimed an improving EOL care.Conclusions. DELEtCC disseminated education representing best EOL practices, and participants used this knowledge to create and implement goals aimed at improving EOL care.     

Spiritual well‐being of Italian advanced cancer patients in the home palliative care setting

This study evaluates the spiritual well‐being (SpWB) in very advanced cancer patients assisted by the home palliative care program of ANT Foundation, a no‐profit Italian organisation. SpWB was assessed by the Functional Assessment of Chronic Illness Therapy–Spiritual Well‐Being Scale (FACIT‐Sp12), including Meaning, Peace, and Faith subscales. The quality‐of‐life (QoL) was evaluated by using the Functional Assessment of Cancer Therapy‐General scale. Questionnaires were distributed to 1,055 patients and 683 were compiled and evaluable for analysis. The mean scores of FACIT‐Sp12 as well as of QoL were notably lower than reference values for cancer survivors. The FACIT‐Sp12 score was higher in patients with less impaired Karnofsky Performance Status, fully participating in religious rituals and living in central Italy. A high Pearson's correlation was found between QoL and FACIT‐Sp12 (r = .60), Peace (r = .71) and Meaning (r = .52), while it was marginal for Faith (r = .27). The hierarchical regression analysis showed that FACIT‐Sp12 is a significant predictor of QoL. The study suggests that Italian patients with advanced cancer assisted by expert multi‐professional teams in the home palliative care setting have a low level of SpWB thereby highlighting the need for the integration of spiritual support as part of comprehensive cancer care.     

Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations

Little of the research involving individuals undergoing testing for BRCA1/2 mutations has examined the effect of genetic counseling and testing on diet, exercise, and vitamin use. This study examined diet, exercise, and vitamin use among 120 Ashkenazi Jewish individuals with a personal and/or family history of breast and/or ovarian cancer who presented for BRCA1/2 genetic counseling and testing. Health behaviors were measured at pre-counseling and 6 months post-results. T-tests or ANOVAs were used to test for association of health behaviors with potential predictors: personal cancer history, anxiety, perceived cancer risk, gene status, and perceived efficacy of health behaviors. Multivariable linear regression analysis found gender (P = .007) and perceived efficacy of a healthy diet (P = .005) to be significantly associated with healthy food consumption; gender (P = .003), education (P = .01), and personal cancer history (P = .02) were significantly associated with unhealthy food consumption; higher age (P < .001) and perceived efficacy (P < .001) were significantly associated with higher vitamin use. Paired t-tests found no significant changes in diet, vitamin use, and exercise as a result of genetic counseling and testing. We conclude that genetic counseling and testing had little impact on health behaviors. Rather, perceived efficacies of certain health behaviors to prevent or delay cancer may be more reliable predictors of those behaviors. Clinicians should assess perceived efficacies of health behaviors in their interventions to improve healthy practices in the BRCA1/2 genetic testing population.     

Disruption to radiation therapy sessions due to anxiety among patients receiving radiation therapy to the head and neck area can be predicted using patient self-report measures

Objective: This analysis sought to determine whether patient self‐report measures were associated with disruption to radiation therapy sessions due to anxiety among cancer patients undergoing radiation therapy to the head and neck region. Method: A cohort of patients undergoing radiation therapy to the head and neck region at a major regional radiation oncology treatment centre (ROTC) in Australia completed self‐report measures of anxiety, history of panic and fears relevant to use of an immobilising mask. The treating Radiation Therapist (RT) rated the level of session disruption due to patient anxiety during the Computerised Tomography/Simulation (CT/Sim) (baseline) session and first treatment session. Results: Complete data were obtained for 90 patients. RTs rated 11 and 24% of patients as having some level of session disruption session due to anxiety at baseline and Treatment 1, respectively. Five factors were significantly associated with session disruption at baseline in bivariate analyses: currently taking psycho‐active medication (p=0.008); fear of enclosed spaces (p=0.006); fear of face being covered up (p=0.006); fear of movement restriction (p=0.041) and ever had an anxiety attack (p=0.034). Sensitivity ranged from 0.57 to 0.75 and specificity ranged from 0.68 to 0.90. Only session disruption at baseline predicted disruption at Treatment 1 (p<0.01). Conclusions: This study offers some preliminary insights into the prevalence of patient anxiety severe enough to cause session disruption and patient self‐report measures which might be used to flag patients for prophylactic treatment. Further development and replication in a larger sample is warranted before introduction of these measures into routine practice. Copyright © 2010 John Wiley & Sons, Ltd.     

From Surviving to Thriving: A Health and Wellness Colloquium for Breast Cancer Survivors

Recent evidence demonstrates that exercise training can provide numerous physical and psychosocial benefits for breast cancer (BCa) survivors. However, educational training programs designed to disseminate exercise training information to survivors are scarce. The From Surviving to Thriving (FST) Colloquium was a one-and-a-half-day event that featured presentations on wellness topics from fitness and health to the latest research in nutrition and exercise. Attendees filled out demographic questionnaires and feedback surveys to assess the impact of the Colloquium. Overall, the FST Colloquium was well received by BCa survivors and health care providers (HCPs). The majority of BCa survivors (84.4%) and HCPs (93.3%) rated their Colloquium experience as very good. Prior to attending the Colloquium, only 8.9% of BCa survivors rated their self-perceived knowledge of exercise and nutrition as excellent. After participation in the Colloquium, this increased to 44.4%. The Colloquium was also successful in influencing planned and actual behavior changes in BCa survivors.